Amgen Inc. (BCBA:AMGN)

Market Cap	216.26T
Revenue (ttm)	41.61T
Net Income (ttm)	7.89T
Shares Out	n/a
EPS (ttm)	14,574.49
PE Ratio	27.42
Forward PE	13.68
Dividend	265.24 (2.07%)
Ex-Dividend Date	Aug 22, 2025

Volume	2,141
Average Volume	2,165
Open	12,975
Previous Close	12,825
Day's Range	12,975 - 13,175
52-Week Range	9,500 - 14,000
Beta	n/a
RSI	61.72
Earnings Date	Oct 30, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD